🔗 Share this article Users Coming Off Weight-Loss Injections Gain Back Weight Far More Rapidly Compared to People Using Diet and Exercise Obesity treatment involves long-term strategies. A recent study reveals that individuals who come off blockbuster slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise programs. Published data in a leading health publication shows that while obese people frequently drop about a fifth of their total mass while on the medication, the mass returns at an estimated rate of nearly a kilo each month after stopping. "Individuals purchasing these drugs must be cognizant of the potential of fast weight regain when the treatment ends," cautioned researcher Dr. Susan Jebb. Such speed of recovery suggests a return to pre-treatment mass within about a year and a half. Analyzing Treatments The research, which reviewed 37 of studies involving thousands of patients, compared the effects of these new drugs with other pills. The team point out that individuals who lose weight through dieting generally experience a more gradual weight regain—perhaps 100 grams monthly—post-intervention. Explaining the Quick Regain Doctors suggest the mechanism of the jabs explains the heightened rebound. These medications imitate a natural hormone called glucagon-like peptide-1, which moderates appetite. "Sustained high doses of the hormone concentrations far above than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher. "Stopping of this GLP-1 'fix' means appetite is unsuppressed, making excessive eating far more likely." A Lifelong Disease? Medical guidelines suggest the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes. A number of clinicians contend that, considering the high risk of relapse, the treatment might need to be ongoing. This view is supported by drug manufacturers, who say that the findings "underscore the long-term character of excess weight," akin to managing diseases like high blood pressure. User Testimonies People who have come off the jabs report a intense return of cravings. "It felt as if a trigger flipping and you're instantly ravenous," described one woman. This challenge is worsened if individuals have not established lasting dietary or behavioural modifications during therapy. Significant Adoption Figures suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow. Adoption is greater among women than men. The middle-aged demographic shows the highest usage rates. Many obtain the drugs through private healthcare rather than the NHS. Finally, clinicians emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone fix and long-term success hinges on integrated lifestyle changes.
Obesity treatment involves long-term strategies. A recent study reveals that individuals who come off blockbuster slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise programs. Published data in a leading health publication shows that while obese people frequently drop about a fifth of their total mass while on the medication, the mass returns at an estimated rate of nearly a kilo each month after stopping. "Individuals purchasing these drugs must be cognizant of the potential of fast weight regain when the treatment ends," cautioned researcher Dr. Susan Jebb. Such speed of recovery suggests a return to pre-treatment mass within about a year and a half. Analyzing Treatments The research, which reviewed 37 of studies involving thousands of patients, compared the effects of these new drugs with other pills. The team point out that individuals who lose weight through dieting generally experience a more gradual weight regain—perhaps 100 grams monthly—post-intervention. Explaining the Quick Regain Doctors suggest the mechanism of the jabs explains the heightened rebound. These medications imitate a natural hormone called glucagon-like peptide-1, which moderates appetite. "Sustained high doses of the hormone concentrations far above than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher. "Stopping of this GLP-1 'fix' means appetite is unsuppressed, making excessive eating far more likely." A Lifelong Disease? Medical guidelines suggest the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes. A number of clinicians contend that, considering the high risk of relapse, the treatment might need to be ongoing. This view is supported by drug manufacturers, who say that the findings "underscore the long-term character of excess weight," akin to managing diseases like high blood pressure. User Testimonies People who have come off the jabs report a intense return of cravings. "It felt as if a trigger flipping and you're instantly ravenous," described one woman. This challenge is worsened if individuals have not established lasting dietary or behavioural modifications during therapy. Significant Adoption Figures suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow. Adoption is greater among women than men. The middle-aged demographic shows the highest usage rates. Many obtain the drugs through private healthcare rather than the NHS. Finally, clinicians emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone fix and long-term success hinges on integrated lifestyle changes.